News & Trends - Pharmaceuticals
Genentech launches phase III trial to treat patients with COVID-19 pneumonia

Genentech, a member of the Roche Group, will launch a phase III clinical trial in April to evaluate the safety and efficacy of intravenous Actemra (tocilizumab) plus standard of care in hospitalised adult patients with severe COVID-19 pneumonia.
Actemra was the first humanised interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide enough relief.
The primary and secondary endpoints of this COVID-19 study include clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables. Patients will be followed for 60 days post-randomisation, and an interim analysis will be conducted to look for early evidence of efficacy.
HCP engagement during COVID-19. Fill the gap of reduced fieldforce activities. Health Industry Hub combines expertise in delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.
To date, several independent clinical trials have begun globally to explore the efficacy and safety of Actemra for the treatment of patients with COVID-19 pneumonia. However, this new trial is vital because there are no well-controlled studies and limited published evidence on the safety or efficacy of Actemra in the treatment of patients suffering from COVID-19.
Actemra is under study as a COVID-19 treatment in two active Chinese clinical studies, according to the Chinese Clinical Trials Registry:
- A 150-patient trial assessing Actemra in combination with favipiravir, a broad spectrum anti-viral agent (ChiCTR2000030894), led by Hong Zhao of Peking University First Hospital.
- A 188-patient trial assessing Actemra alone (ChiCTR2000029765), led by Dongsheng Wang of The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital).
Register FREE and join 20,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
Digital & Innovation

Reimagining remote care with Australia’s first virtual hospital
Australia’s first virtual hospital is taking on a new role as a national testbed for advancing the future of patient-facing […]
MoreNews & Trends - MedTech & Diagnostics

Health Minister and Opposition face off at the National Press Club
In a blistering showdown at the National Press Club, Federal Health Minister, Mark Butler, and his Opposition counterpart Senator Anne […]
MoreNews & Trends - Pharmaceuticals

GSK nabs label expansion for RSV vaccine
Coinciding with World Immunisation Week (24-30 April), GSK has secured TGA approval for its respiratory syncytial virus (RSV) vaccine, marking […]
MoreNews & Trends - MedTech & Diagnostics

Low-value imaging linked to high human cost
Imagining has become a cornerstone of modern medicine, for their ability to detect cancers, guide surgeries, and uncover internal injuries […]
More